BPC-157 vs SS-31

BPC-157 and SS-31 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157, a synthetic peptide composed of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight ~1419.5 g/mol), is derived from a naturally occurring protein in human gastric juice. Research indicates that BPC-157 exhibits significant regenerative properties, promoting healing in various tissues including tendons, ligaments, muscles, bones, nerves, and the gastrointestinal tract. Numerous animal studies have demonstrated its cytoprotective effects, yet human clinical data remains scarce, with only three pilot studies published to date—one focusing on knee pain (n=16), another on interstitial cystitis (n=12), and a third assessing intravenous safety (n=2). The peptide is classified by the FDA as Category 2, implying significant safety concerns and prohibiting compounding, and it is banned by WADA in competitive sports. Key claims associated with BPC-157 include its potential to accelerate tendon and ligament healing, repair gut lining, and reverse NSAID-induced gastrointestinal damage.

SS-31, also known as Elamipretide, is a tetrapeptide designed to target mitochondria. It selectively accumulates in the inner mitochondrial membrane, where it binds to cardiolipin, a phospholipid vital for mitochondrial function, thereby stabilizing the cristae structure. This mechanism is pivotal in mitigating mitochondrial dysfunction, which is implicated in various diseases, including heart failure and age-related conditions. SS-31 has progressed through multiple Phase I to III clinical trials, notably the TAZPOWER trial aimed at Barth syndrome, demonstrating a commitment to evaluating its therapeutic potential. Clinical findings suggest that SS-31 may enhance mitochondrial function and reduce cardiac dysfunction, with emerging research hinting at possible anti-aging effects. The body of evidence surrounding SS-31 is more robust than that of BPC-157, providing a stronger foundation for its applications in mitochondrial research and therapy.

BPC-157 and SS-31 serve distinct yet complementary roles in research. BPC-157 is primarily investigated for its applications in injury recovery and gastrointestinal health, reflecting its regenerative properties. In contrast, SS-31 is focused on areas related to anti-aging and metabolic health, particularly through its effects on mitochondrial function. While both peptides contribute to the broader field of regenerative medicine, their specific mechanisms and targeted applications differ significantly. This divergence necessitates careful consideration by researchers when selecting a peptide for studies related to healing, mitochondrial health, or age-related conditions.

The safety profiles of BPC-157 and SS-31 reveal important distinctions. For BPC-157, there are no completed randomized controlled trials assessing human safety, although preclinical studies across various species have shown no toxic or lethal dose thresholds in ranges from 6 mcg/kg to 20 mg/kg. Despite this, the FDA previously classified it as Category 2 due to significant safety concerns, although this classification was removed on April 15, 2026. A PCAC review is pending in July 2026 to evaluate compounding eligibility. The FDA has highlighted insufficient human safety data and potential risks of immunogenicity. In contrast, SS-31 has demonstrated a generally favorable safety profile in clinical trials, with mild adverse effects such as headaches, dizziness, and nausea reported. No significant safety signals were identified in Phase I and II trials, suggesting a well-tolerated profile in the tested populations.